PBH Stock Analysis: Prestige Brand Holdings | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.242m USD | 12M Return: -40% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.0M
EPS Trend: 33.5%
Qual. Beats: -1
Rev. Trend: -70.1%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Prestige Consumer Healthcare Inc. (NYSE: PBH), formerly Prestige Brands Holdings until its 2018 renaming, is a U.S.-based consumer healthcare company founded in 1996 and headquartered in Tarrytown, New York. It develops, manufactures, and distributes over-the-counter (OTC) health and personal care products across two reporting segments: North American OTC Healthcare and International OTC Healthcare, with operations spanning North America, Australia, and other international markets.
The company operates a brand-portfolio model built around established niche OTC and personal care labels rather than a single pipeline-driven franchise. Its portfolio spans more than a dozen consumer healthcare brands, including analgesics (BC, Goodys), baby care (Boudreauxs Butt Paste), sore throat relief (Chloraseptic), eye care (Clear Eyes, TheraTears), wart removal (Compound W), ear care (Debrox), oral care (DenTek), motion sickness (Dramamine), gastrointestinal health (Fleet, Gaviscon), cough/throat (Ludens), womens health (Monistat, Summers Eve), lice treatment (Nix), and hydration/respiratory care (Fess, Hydralyte).
Distribution is primarily retail, covering mass merchandisers and drug, food, dollar, convenience, and club stores, supplemented by e-commerce channels. As a GICS-classified Pharmaceuticals sub-industry company within Health Care, Prestige competes in the consumer healthcare segment, where products are sold without a prescription and brand equity, shelf placement, and advertising typically drive category share.
- North American OTC Healthcare segment revenue trends drive consensus
- International segment expansion in Australia and New Zealand boosts margins
- Leveraged balance sheet limits capital allocation and buyback flexibility
| Net Income: 190.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.02 > 1.0 |
| NWC/Revenue: 28.53% < 20% (prev 30.03%; Δ -1.51% < -1%) |
| CFO/TA 0.07 > 3% & CFO 265.4m > Net Income 190.3m |
| Net Debt (1.03b) to EBITDA (331.1m): 3.11 < 3 |
| Current Ratio: 3.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -4.78% < -2% |
| Gross Margin: 53.96% > 18% (prev 56.27%; Δ -2.31% > 0.5%) |
| Asset Turnover: 31.33% > 50% (prev 33.44%; Δ -2.11% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBIT TTM 299.8m / Interest Expense TTM 42.3m) |
| A: 0.09 (Total Current Assets 431.5m - Total Current Liabilities 120.9m) / Total Assets 3.55b |
| B: 0.49 (Retained Earnings 1.75b / Total Assets 3.55b) |
| C: 0.09 (EBIT TTM 299.8m / Avg Total Assets 3.47b) |
| D: 1.14 (Book Value of Equity 1.89b / Total Liabilities 1.66b) |
| Altman-Z'' = 3.95 = AA |
| DSRI: 1.03 (Receivables 191.9m/194.3m, Revenue 1.09b/1.14b) |
| GMI: 1.04 (GM 56.27% / 53.96%) |
| AQI: 1.00 (AQ_t 0.83 / AQ_t-1 0.83) |
| SGI: 0.96 (Revenue 1.09b / 1.14b) |
| TATA: -0.02 (NI 190.3m - CFO 265.4m) / TA 3.55b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 47.27 with a total of 726,173 shares traded. Over the past week, the price has changed by +1.78%, over one month by +4.81%, over three months by -16.50% and over the past year by -40.04%.
Current recommended Stop Loss: 44.50 (which is 5.9% or 1.4 ATR below the current price).
Prestige Brand Holdings has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold PBH.
- StrongBuy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 66.8 | 41.3% |
P/E Trailing = 11.7711
P/E Forward = 10.2564
P/S = 2.059
P/B = 1.1557
P/EG = 1.3954
Revenue TTM = 1.09b USD
EBIT TTM = 299.8m USD
EBITDA TTM = 331.1m USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 1.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 48.5m
Net Debt = 1.03b USD (calculated: Debt 1.09b - CCE 63.9m)
Enterprise Value = 3.27b USD (2.24b + Debt 1.09b - CCE 63.9m)
Interest Coverage Ratio = 7.08 (Ebit TTM 299.8m / Interest Expense TTM 42.3m)
EV/FCF = 12.87x (Enterprise Value 3.27b / FCF TTM 254.2m)
FCF Yield = 7.77% (FCF TTM 254.2m / Enterprise Value 3.27b)
FCF Margin = 23.35% (FCF TTM 254.2m / Revenue TTM 1.09b)
Net Margin = 17.48% (Net Income TTM 190.3m / Revenue TTM 1.09b)
Gross Margin = 53.96% ((Revenue TTM 1.09b - Cost of Revenue TTM 501.3m) / Revenue TTM)
Gross Margin QoQ = 50.02% (prev 55.52%)
Tobins Q-Ratio = 0.92 (Enterprise Value 3.27b / Total Assets 3.55b)
Interest Expense / Debt = 3.87% (Interest Expense 42.3m / Debt 1.09b)
Taxrate = 26.10% (67.2m / 257.5m)
NOPAT = 221.6m (EBIT 299.8m * (1 - 26.10%))
Current Ratio = 3.57 (Total Current Assets 431.5m / Total Current Liabilities 120.9m)
Debt / Equity = 0.58 (Debt 1.09b / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = 3.11 (Net Debt 1.03b / EBITDA 331.1m)
Debt / FCF = 4.05 (Net Debt 1.03b / FCF TTM 254.2m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 190.3m / Total Assets 3.55b)
RoE = 10.29% (Net Income TTM 190.3m / Total Stockholder Equity 1.85b)
RoCE = 10.55% (EBIT 299.8m / Capital Employed (Equity 1.85b + L.T.Debt 994.0m))
RoIC = 6.55% (NOPAT 221.6m / Invested Capital 3.38b)
WACC = 5.47% (E(2.24b)/V(3.34b) * Re(6.74%) + D(1.09b)/V(3.34b) * Rd(3.87%) * (1-Tc(0.26)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -2.19%
[DCF] Terminal Value 76.02% ; FCFF base≈249.9m ; Y1≈260.3m ; Y5≈296.7m
[DCF] Fair Price = 74.91 (EV 4.58b - Net Debt 1.03b = Equity 3.55b / Shares 47.4m; r=8.35% [WACC [floored]]; 5y FCF grow 4.50% → 2.50% )
EPS Correlation: 33.49 | EPS CAGR: 1.38% | SUE: -2.33 | # QB: -1
Revenue Correlation: -70.07 | Revenue CAGR: -0.97% | SUE: -1.28 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.15 | Chg30d=+0.22% | Revisions=-20% | Analysts=2
EPS current Year (2027-03-31): EPS=4.61 | Chg30d=-4.13% | Revisions=-64% | GrowthEPS=+5.2% | GrowthRev=+12.8%
EPS next Year (2028-03-31): EPS=5.02 | Chg30d=-0.51% | Revisions=-20% | GrowthEPS=+8.9% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: -64%